Literature DB >> 34359079

Serum Cotinine and Adverse Cardiovascular Outcomes: A Cross-sectional Secondary Analysis of the nuMoM2b Heart Health Study.

Lauren H Theilen1, Rebecca B McNeil2, Shannon Hunter3, William A Grobman4, Corette B Parker3, Janet M Catov5, Victoria L Pemberton6, Deborah B Ehrenthal7, David M Haas8, Matthew K Hoffman9, Judith H Chung10, Farhana Mukhtar10, Zorayr Arzumanyan11, Brian Mercer12, Samuel Parry13, George R Saade14, Hyagriv N Simhan15, Ronald J Wapner16, Robert M Silver1.   

Abstract

OBJECTIVE: We aimed to (1) compare serum cotinine with self-report for ascertaining smoking status among reproductive-aged women; (2) estimate the relative odds of adverse cardiovascular (CV) outcomes among women by smoking status; (3) assess whether the association between adverse pregnancy outcomes (APOs) and CV outcomes varies by smoking status. STUDY
DESIGN: We conducted a cross-sectional study of the nuMoM2b Heart Health Study. Women attended a study visit 2 to 7 years after their first pregnancy. The exposure was smoking status, determined by self-report and by serum cotinine. Outcomes included incident chronic hypertension (HTN), metabolic syndrome (MetS), and dyslipidemia. Multivariable logistic regression estimated odds ratios (ORs) for each outcome by smoking status.
RESULTS: Of 4,392 women with serum cotinine measured, 3,610 were categorized as nonsmokers, 62 as secondhand smoke exposure, and 720 as smokers. Of 3,144 women who denied tobacco smoke exposure, serum cotinine was consistent with secondhand smoke exposure in 48 (1.5%) and current smoking in 131 (4.2%) After adjustment for APOs, smoking defined by serum cotinine was associated with MetS (adjusted OR [aOR] = 1.52, 95% confidence interval [CI]: 1.21, 1.91) and dyslipidemia (aOR = 1.28, 95% CI: 1.01, 1.62). When stratified by nicotine exposure, nonsmokers with an APO in their index pregnancy had higher odds of stage 1 (aOR = 1.64, 95% CI: 1.32, 2.03) and stage 2 HTN (aOR = 2.92, 95% CI: 2.17, 3.93), MetS (aOR = 1.76, 95% CI: 1.42, 2.18), and dyslipidemia (aOR = 1.55, 95% CI: 1.25, 1.91) relative to women with no APO. Results were similar when smoking exposure was defined by self-report.
CONCLUSION: Whether determined by serum cotinine or self-report, smoking is associated with subsequent CV outcomes in reproductive-aged women. APOs are also independently associated with CV outcomes in women. KEY POINTS: · Cotinine was detected in 5.7% of reported nonsmokers.. · Smoking and APOs were independently associated with CV health.. · Smoking was associated with MetS and dyslipidemia.. Thieme. All rights reserved.

Entities:  

Year:  2021        PMID: 34359079      PMCID: PMC8818058          DOI: 10.1055/a-1580-3155

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   3.079


  30 in total

1.  A description of the methods of the Nulliparous Pregnancy Outcomes Study: monitoring mothers-to-be (nuMoM2b).

Authors:  David M Haas; Corette B Parker; Deborah A Wing; Samuel Parry; William A Grobman; Brian M Mercer; Hyagriv N Simhan; Matthew K Hoffman; Robert M Silver; Pathik Wadhwa; Jay D Iams; Matthew A Koch; Steve N Caritis; Ronald J Wapner; M Sean Esplin; Michal A Elovitz; Tatiana Foroud; Alan M Peaceman; George R Saade; Marian Willinger; Uma M Reddy
Journal:  Am J Obstet Gynecol       Date:  2015-01-31       Impact factor: 8.661

2.  Consequences of smoking during pregnancy on maternal health.

Authors:  Jennifer Roelands; Margaret G Jamison; Anne D Lyerly; Andra H James
Journal:  J Womens Health (Larchmt)       Date:  2009-06       Impact factor: 2.681

3.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Circulation       Date:  2018-10-23       Impact factor: 29.690

4.  A United States national reference for fetal growth.

Authors:  G R Alexander; J H Himes; R B Kaufman; J Mor; M Kogan
Journal:  Obstet Gynecol       Date:  1996-02       Impact factor: 7.661

5.  Cardiovascular Disease-Related Morbidity and Mortality in Women With a History of Pregnancy Complications.

Authors:  Sonia M Grandi; Kristian B Filion; Sarah Yoon; Henok T Ayele; Carla M Doyle; Jennifer A Hutcheon; Graeme N Smith; Genevieve C Gore; Joel G Ray; Kara Nerenberg; Robert W Platt
Journal:  Circulation       Date:  2019-02-19       Impact factor: 29.690

6.  Duration of pregnancy, even at term, predicts long-term risk of coronary heart disease and stroke mortality in women: a population-based study.

Authors:  Janet W Rich-Edwards; Kari Klungsoyr; Allen J Wilcox; Rolv Skjaerven
Journal:  Am J Obstet Gynecol       Date:  2015-06-10       Impact factor: 8.661

Review 7.  Preeclampsia and Future Cardiovascular Health: A Systematic Review and Meta-Analysis.

Authors:  Pensée Wu; Randula Haththotuwa; Chun Shing Kwok; Aswin Babu; Rafail A Kotronias; Claire Rushton; Azfar Zaman; Anthony A Fryer; Umesh Kadam; Carolyn A Chew-Graham; Mamas A Mamas
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-02-22

8.  Smoking during pregnancy: comparison of self-reports and cotinine levels in 496 women.

Authors:  Rune Lindqvist; Lena Lendahls; Orjan Tollbom; Hans Aberg; Anders Håkansson
Journal:  Acta Obstet Gynecol Scand       Date:  2002-03       Impact factor: 3.636

9.  Risks for premature rupture of amniotic membranes.

Authors:  E E Ekwo; C A Gosselink; R Woolson; A Moawad
Journal:  Int J Epidemiol       Date:  1993-06       Impact factor: 7.196

10.  Metabolism of nicotine to cotinine studied by a dual stable isotope method.

Authors:  N L Benowitz; P Jacob
Journal:  Clin Pharmacol Ther       Date:  1994-11       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.